We are delighted to report that after months of assessment and review, taking into account the views from a Patient and Clinician Engagement (PACE) meeting, that the Roche drug entrectinib (Rozlytrek) has been accepted by the Scottish Medicines Consortium for use by NHS Scotland as monotherapy for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
This includes GIST patients whose cancer is driven by an NTRK fusion.
In a pooled analysis of three phase I/II studies in adults with metastatic or locally advanced NTRK fusion-positive solid tumours, 64% of patients achieved an objective response with entrectinib treatment.
This is a very new type of therapy that relies upon genomic sequencing to identify if this fusion exists as the driver of a patients tumour.
Entrectinib was approved by NICE for English patients in June 2020
More information can be found via this link .